Ipsen's Stock Rises by 2.99%, Leading the SBF 120

A Significant Increase that Positions the Stock at the Top of the SBF 120

Ipsen's stock gains 2.99% to €161.90, marking the highest increase in the SBF 120 while the index itself falls by 0.76%. This movement contrasts with the general market atmosphere, as the CAC 40 drops by 0.74% and the DAX by 1.53%, in a tense bond environment characterized by a more restrictive turn from major central banks and a rise in the VIX by 18%. The stock has moved back above its short-term moving averages, after dipping below the MM20 and MM50 in recent days.

The price is now 3.64% above the MM20 (€156.21) and remains slightly above the MM50 (€160.74), while the gap with the MM200 at €139.73 reaches nearly 16%, reflecting a well-oriented underlying trend (+60% over a year). The RSI at 48 remains neutral and leaves room before reaching the overbought zone, as the stock approaches the resistance identified at €166, which was tested but not surpassed in previous sessions.

An Active Clinical Pipeline Following Recent Data on Iqirvo

The rebound follows clinical data presented at the end of May at the EASL congress, which confirmed the effectiveness of Iqirvo in primary biliary cholangitis, with improvements observed in 67% of patients according to the details shared during the presentation at the EASL congress in late May 2026. Growth opportunities mentioned at that time also included a significant reduction in alkaline phosphatases in the studied population. The pipeline remains active, with several Phase III readings expected in the coming months as previously communicated by the laboratory.

On the governance side, the AMF granted Beech Tree an exemption from the obligation to file a public offer at the beginning of April, a topic that remains in the background of the shareholder situation. The resistance at €166 marks the next technical threshold to observe to confirm the exit from the consolidation phase that began in mid-May.